Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04453826
Other study ID # SYSUCC-MYC-2020-1103
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 1, 2020
Est. completion date September 2028

Study information

Verified date September 2020
Source Sun Yat-sen University
Contact Ming-Yuan Chen, MD, PhD
Phone : 86-20-87343624
Email chmingy@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of high risk patients with nasopharyngeal carcinoma compared with those treated with chemo-radiotherapy alone.


Description:

Through multicenter, open-label, randomised clinical trials, high risk patients with nasopharyngeal carcinoma (staged as II-III with SD/PD according to RECIST criteria or EBV DNA of >0 copies/mL after 3 cycles of GP induction chemotherapy and staged as IVa) are randomized into camrelizumab plus chemo-radiotherapy arm and chemo-radiotherapy arm. The efficacy and safety of patients between these two arms are compared.


Recruitment information / eligibility

Status Recruiting
Enrollment 388
Est. completion date September 2028
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Histologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or type III).

2. Staged as T4N0-2M0,T1-4N3M0 (stage IVa) at diagnosis (according to the 8th AJCC edition).

3. Staged as T1-3N1-2M0, T2-3N0M0 (stage II-III) with SD/PD according to RECIST criteria or EBV DNA of >0 copies/mL after 3 cycles of GP induction chemotherapy.

4. Aged between 18-70 years.

5. Karnofsky scale (KPS)=70.

6. Normal bone marrow function.

7. Normal liver and kidney function:

1. total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal limit;

2. creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5 times the upper normal limit.

8. Given written informed consent.

Exclusion Criteria:

1. Histologically confirmed keratinized squamous cell carcinoma (WHO type I) or basal squamous cell carcinoma.

2. Recurrent or metastatic nasopharyngeal carcinoma.

3. Staged as II-III which is evaluated as PR or CR and EBV DNA of 0 copies/mL after 3 cycles of GP induction chemotherapy.

4. Has known allergy to large molecule protein products or any compound of study therapy.

5. Has known subjects with other malignant tumors.

6. Has any active autoimmune disease or history of autoimmune disease.

7. Has a history of psychiatric substance abuse, alcoholism, or drug addiction.

8. The laboratory examination value does not meet the relevant standards within 7 days before enrollment

9. Received a systematic glucocorticoid therapy within 4 weeks of the first dose of study medication.

10. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB with 1 year.

11. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent.

12. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy). Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) will be allowed to enroll.

13. Has a known history of human immunodeficiency virus (HIV).

14. Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of =1000cps/ml or hepatitis C virus (HCV) antibody positive.

15. Has received a live vaccine within 4 weeks of planned start of study therapy.

16. Pregnancy or breast feeding.

Study Design


Intervention

Drug:
Camrelizumab plus chemo-radiotherapy
Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy
Chemo-radiotherapy alone
Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy

Locations

Country Name City State
China Cancer Center of Guangzhou Medical University Guangzhou Guangdong
China Sun Yat-sen University Cancer Center Guangzhou Guangdong
China Yuebei People's Hospital Shaoguan Guangdong
China Wuzhou Red Cross Hospital Wuzhou Guangxi
China Zhongshan People's Hospital Zhongshan Guangdong
China The Fifth Affiliated Hospital of Sun Yat-sen University Zhuhai Guangdong

Sponsors (6)

Lead Sponsor Collaborator
Sun Yat-sen University Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Fifth Affiliated Hospital, Sun Yat-Sen University, Wuzhou Red Cross Hospital, Yuebei People's Hospital, Zhongshan People's Hospital, Guangdong, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progress-free survival (PFS) Defined as time from randomization to locoregional or distant metastasis relapse or death from any cause, whichever occurred first. 3 years
Secondary Overall Survival (OS) Defined as the time interval from randomization to death due to any cause. 3 years
Secondary Distant Metastasis-Free Survival (DMFS) Defined as the time interval from randomisation to the date of first distant metastases. 3 years
Secondary Locoregional Relapse-Free Survival (LRRFS) Defined as the time from randomisation to the date of first locoregional relapse. 3 years
Secondary Incidence of treatment related acute complications The proportion of patients with treatment related acute complications according to NCI-CTC5.0 criteria and RTOG criteria. up to 1 years
Secondary Incidence of treatment related late complications The proportion of patients with treatment related late complications according to NCI-CTC5.0 criteria and RTOG criteria. up to 3 years
Secondary Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) before treatment, during treatment, after treatment. up to 3 years
Secondary Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35) Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35) before treatment, during treatment, after treatment. up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT03212742 - Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients Phase 1/Phase 2
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Withdrawn NCT02542137 - Abscopal Effect for Metastatic Small Cell Lung Cancer Phase 2
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Completed NCT01168479 - FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer Phase 3
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Completed NCT03280719 - Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions N/A
Recruiting NCT05514327 - A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL N/A
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT03370926 - FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy N/A
Active, not recruiting NCT03870919 - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients N/A
Active, not recruiting NCT02428049 - Radiation Pneumonitis After SBRT for NSCLC
Recruiting NCT04923620 - Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
Active, not recruiting NCT05371795 - Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device N/A
Recruiting NCT03210428 - Quantitative MR Imaging in Locally Advanced Cervical Cancer
Recruiting NCT05364411 - HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC N/A